摘要
目的 评价丙硫氧嘧啶和甲巯咪唑治疗甲状腺功能亢进症(甲亢)患者的临床疗效与安全性。方法 84例甲亢患者,按随机数字表法分为对照组和观察组,每组42例。对照组患者采取丙硫氧嘧啶治疗,观察组患者采取甲巯咪唑治疗。对比两组患者临床疗效、治疗前后甲状腺功能指标[血清游离三碘甲状腺原氨酸(FT3)、血清游离甲状腺素(FT4)、促甲状腺激素(TSH)]水平及用药不良反应发生情况。结果 观察组患者的治疗总有效率95.24%高于对照组的76.19%,差异具有统计学意义(P<0.05)。治疗后,观察组患者的FT3(8.61±1.48)pmol/L、FT4(20.81±2.86)pmol/L均低于对照组的(11.43±1.59)、(27.68±2.91)pmol/L, TSH(1.45±0.13)μIU/ml高于对照组的(0.63±0.09)μIU/ml,差异具有统计学意义(P<0.05)。观察组患者用药不良反应发生率4.76%低于对照组的23.81%,差异具有统计学意义(P<0.05)。结论 甲亢患者采取甲巯咪唑治疗的疗效显著优于丙硫氧嘧啶,且安全性更高。因此,可择优选择使用甲巯咪唑进行临床治疗。
Objective To evaluate the clinical efficacy and safety of propylthiouracil and methimazole in the treatment of hyperthyroidism.Methods A total of 84 patients with hyperthyroidism were divided into control group and observation group according to the random numerical table,with 42 cases in each group.Patients in the control group were treated with propylthiouracil,and patients in the observation group were treated with methimazole.Both groups were compared in terms of clinical efficacy,thyroid function indexes[serum free triiodothyronine(FT_(3)),serum free thyroxine(FT_(4)),thyroid-stimulating hormone(TSH)]levels before and after treatment,and occurrence of adverse drug reactions.Results The total effective rate of treatment 95.24%in the observation group was higher than 76.19% in the control group,and the difference was statistically significant(P<0.05).After treatment,the FT3(8.61±1.48)pmol/L and FT4(20.81±2.86)pmol/L of the observation group were lower than(11.43±1.59)and(27.68±2.91)pmol/L of the control group,and the TSH(1.45±0.13)μIU/ml was higher than(0.63±0.09)μIU/ml of the control group.All the differences were statistically significant(P<0.05).The incidence of adverse drug reactions 4.76%in the observation group was lower than 23.81%in the control group,and the difference was statistically significant(P<0.05).Conclusion Methimazole is significantly more effective and safer than propylthiouracil in patients with hyperthyroidism;therefore,methimazole is the preferred choice for clinical treatment.
作者
崔国英
CUI Guo-ying(Liaoning disabled Service Center,Shenyang 110015,China)
出处
《中国现代药物应用》
2021年第23期136-138,共3页
Chinese Journal of Modern Drug Application
